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GF, but not TGF
 
 
 
, efﬁciently induces degradation of
the EGF receptor (EGFR). We show that EGFR was
initially polyubiquitinated to the same extent upon
incubation with EGF and TGF
 
 
 
, whereas the ubiquitination
was more sustained by incubation with EGF than with
 
TGF
 
 
 
. Consistently, the ubiquitin ligase c-Cbl was recruited
to the plasma membrane upon activation of the EGFR with
 
EGF and TGF
 
 
 
, but localized to endosomes only upon
activation with EGF. EGF remains bound to the EGFR upon
endocytosis, whereas TGF
 
 
 
 dissociates from the EGFR.
Therefore, the sustained polyubiquitination is explained by
EGF securing the kinase activity of endocytosed EGFR.
Overexpression of the dominant negative N-Cbl inhibited
E
 
ubiquitination of the EGFR and degradation of EGF and
EGFR. This demonstrates that EGF-induced ubiquitination
of the EGFR as such is important for lysosomal sorting. Both
lysosomal and proteasomal inhibitors blocked degradation
of EGF and EGFR, and proteasomal inhibitors inhibited
translocation of activated EGFR from the outer limiting
membrane to inner membranes of multivesicular bodies
(MVBs). Therefore, lysosomal sorting of kinase active EGFR
is regulated by proteasomal activity. Immuno-EM showed
the localization of intact EGFR on internal membranes of
MVBs. This demonstrates that the EGFR as such is not the
proteasomal target.
 
Introduction
 
Several transmembrane proteins are ubiquitinated upon
ligation (for reviews see Bonifacino and Weissman, 1998;
Hicke, 1999). The EGF receptor (EGFR)* is polyubiquiti-
nated upon activation of the EGFR intrinsic kinase activity
(Galcheva-Gargova et al., 1995). c-Cbl was recently demon-
strated to possess ubiquitin ligase activity (Joazeiro et al.,
1999), and it was further reported that the NH
 
2
 
-terminal re-
gion of c-Cbl, containing the RING finger responsible for
the ubiquitin ligase activity (Levkowitz et al., 1999), was suf-
ficient to enhance EGFR downregulation (Lill et al., 2000).
c-Cbl has also been demonstrated to negatively regulate
PDGF receptor (PDGFR)-dependent cell proliferation by
ligand-dependent ubiquitination and subsequent degradation
of both PDGFR
 
 
 
 and PDGFR
 
 
 
 (Miyake et al., 1998, 1999).
In accordance with these findings, it has been suggested that
ubiquitination marks receptors for degradation (Hicke, 1997;
Heldin et al., 1998; Levkowitz et al., 1998).
The yeast G protein–coupled receptor Ste2p is accumu-
lated in high molecular weight ubiquitinated forms at the
cell surface in response to the binding of 
 
 
 
-factor in endocy-
tosis-deficient yeast cells (Hicke and Riezman, 1996). This
finding established a link between ligand-induced ubiquiti-
nation, endocytosis, and eventual targeting for vacuolar deg-
radation in yeast. It has also been reported that the ubiquitin
conjugation system is required for ligand-induced endocyto-
sis of the growth hormone receptor (van Kerkhof et al.,
2000). Based on these and other observations, the ubiquitin
system has been suggested as an important regulatory system
for clathrin-dependent endocytosis (Strous and Govers,
1999). This is in accordance with the demonstration that
polyubiquitination of the EGFR occurs at the plasma mem-
brane. We demonstrated that in endocytosis-deficient cells
the EGFR was transiently polyubiquitinated, but not degraded
(Stang et al., 2000).
It is still unclear to what extent proteasomal processing is
involved in downregulation of receptors. In the case of the
PDGFR, the degradation was reportedly inhibited 
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by proteasome inhibitors (Mori et al., 1995a, 1995b). The
receptor tyrosine kinase c-Met consists of a 50-kD extracel-
lular 
 
 
 
 subunit and a 140-kD membrane-spanning 
 
 
 
 sub-
unit. Upon ligand binding, the 
 
 
 
 subunit was ubiquitinated
and subsequently degraded in a proteasome-dependent
manner (Jeffers et al., 1997). Also in the case of ErbB2, pro-
teasome inhibitors have been demonstrated to inhibit degra-
dation (Mimnaugh et al., 1996). However, the question of
whether or not ErbB2 is in fact endocytosed is still contro-
versial. It was recently reported that the antibiotic geldana-
mycin induced degradation of ErbB2 and that degradation
of the COOH-terminal fragment was prevented by protea-
some inhibitors, whereas degradation of the membrane-
anchored 135-kD fragment was blocked by inhibitors of the
endocytosis-dependent degradation pathway (Tikhomirov
and Carpenter, 2000). Therefore, the functional role of
ubiquitination in endocytosis and downregulation of recep-
tors is unresolved and challenging.
It has been established that EGF and TGF
 
 
 
 differ in their
ability to induce processing of the EGFR (Ebner and
Derynck, 1991). EGF is a more acidic molecule than is
TGF
 
 
 
 and remains bound to the EGFR upon internaliza-
tion during acidification of the endocytic vesicle, finally re-
sulting in proteolytic degradation of both ligand and recep-
tor in lysosomes. In contrast, TGF
 
 
 
 rapidly dissociates from
the receptor upon internalization, resulting in recycling of
EGFR to the cell surface (Sorkin and Waters, 1993). We re-
port here that in spite of differential degradation induced by
EGF and TGF
 
 
 
, both ligands equally efficiently induce ini-
tial ubiquitination and endocytosis of the EGFR. However,
EGF, which in contrast to TGF
 
 
 
 secures the kinase activity
of the EGFR upon endocytosis, maintains a sustained poly-
ubiquitination of the EGFR. Consistently, colocalization of
EGFR and c-Cbl on endosomes is observed only upon incu-
bation with EGF. By overexpression of the dominant nega-
tive N-Cbl, we confirmed that Cbl-induced ubiquitination
is important for degradation of EGF-bound EGFR, but not
for endocytosis. By the use of inhibitors of endosomal/lyso-
somal and proteasomal degradation, we further found that
degradation of EGFR and EGF requires proteasomal pro-
cessing. Therefore, we submit that ubiquitination per se is
not a signal for EGFR degradation. However, sustained
ubiquitination is required for efficient sorting of the EGFR
to a degrading compartment, and proteasomal activity is re-
quired for efficient transport of EGF and EGFR to inner
membranes of MVBs.
 
Results
 
EGFR is efficiently degraded upon incubation 
with EGF, but not with TGF
 
 
 
To confirm differential degradation of the EGFR upon in-
cubation with EGF compared with TGF
 
 
 
 (Ebner and
Derynck, 1991), Hep2 cells were incubated with EGF and
TGF
 
 
 
 in the presence of cycloheximide (CHX), facilitating
studies of EGFR degradation by inhibiting protein synthe-
sis. Immunoblotting showed that there was a visible degra-
dation of EGFR already upon incubation with EGF for 2 h
(Fig. 1 A, top). In contrast, there was only a slight degrada-
tion of the EGFR upon incubation with TGF
 
 
 
 for as long
as 7 h (Fig. 1 A, bottom). pH decreases gradually in en-
docytic vesicles. Whereas intravesicular pH is 
 
 
 
6.0 in early
endosomes, the pH of lysosomes is 4.5–5.0 (Yamashiro and
Maxfield, 1984). The EGFR is fully phosphorylated on ice
(unpublished data). However,the phosphorylation is pH
sensitive (Fig. 1 B). In cells incubated with TGF
 
 
 
, the
EGFR became dephosphorylated upon exposure to slightly
reduced pH. The EGFR in cells incubated with EGF was
dephosphorylated only at pH values similar to those found
in lysosomes. These results can be explained by the fact that
TGF
 
 
 
 is released from the EGFR at slightly reduced pH val-
ues, whereas EGF is not. Accordingly, TGF
 
 
 
 will be re-
leased in early endosomes, allowing the EGFR to recycle to
Figure 1.  Degradation and pH dependent phosphorylation of the 
EGFR upon incubation with EGF and TGF . (A) Hep2 cells were 
incubated with CHX (25  g/ml) and EGF (10 nM) (top) or TGF  
(10 nM) (bottom) at 37 C for the indicated time periods. The cells 
were lysed and subjected to SDS-PAGE and immunoblotting with 
antibody to EGFR (Stang et al., 2000). c, control cells not incubated 
with ligand nor CHX. (B) Hep2 cells were incubated with EGF 
(10 nM) or TGF  (10 nM) on ice for 15 min. The medium was 
removed, and the cells were incubated on ice for 20 min in MEM 
without bicarbonate with BSA and MES (10 mM) adjusted to pH 
5.0, 6.0, 7.0 and 7.4, containing EGF (10 nM) or TGF  (10 nM). The 
cells were lysed and subjected to SDS-PAGE and immunoblotting 
with antibody to activated EGFR (pY1173). (C) Hep2 cells were 
incubated with 10 nM EGF ( ) or 10 nM TGF  ( ) at 37 C for 
indicated times, before the cells were biotinylated on ice. Biotinylated 
EGFR was immunoprecipitated and analyzed by SDS-PAGE and 
immunoblotting. Biotinylated EGFR was normalized for precipitation 
efficiency using total EGFR immunoprecipitated. The data represent 
the mean of four independent experiments   SEM. 
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the plasma membrane. However, EGF will remain com-
plexed to the EGFR securing EGFR kinase activity and
thereby lysosomal sorting. The efficiency of endocytosis in-
duced by EGF and TGF
 
 
 
 was assessed by measuring the
amount of surface-localized (noninternalized) EGFR by bio-
tinylation. As demonstrated in Fig. 1 C, and as previously
reported (Decker, 1990; Ebner and Derynck, 1991), EGF
and TGF
 
 
 
 induced endocytosis with the same efficiency.
The difference in intracellular trafficking of the EGFR
upon activation with EGF versus TGF
 
 
 
, was further stud-
ied using immuno-EM. Labeling of thawed cryosections
showed that the early events in endocytosis were identical
upon stimulation with EGF and TGF
 
 
 
. Upon binding of
ligand to cells on ice and subsequent chase at 37
 
 
 
C, the
EGFR was internalized via clathrin coated pits. After a 10-
min chase, the labeling was found in compartments with
tubulovesicular morphology typical of early endosomes
(unpublished data). However, after a 30-min chase, the in-
tracellular labeling pattern and intensity showed ligand-
dependent differences. Whereas with both ligands labeling
was found associated with MVBs (Fig. 2), the morphology
of the EGFR-positive MVBs as well as the localization of the
EGFR within MVBs varied. In cells incubated with TGF
 
 
 
,
labeling intensity was low and mainly found on MVBs con-
taining only a few internal vesicles (Fig. 2, D–E). This possi-
bly represents MVBs at an early stage of formation, and the
labeling was largely restricted to the outer, limiting mem-
brane of the MVBs. However, in cells incubated with EGF,
labeling was found on MVBs at all stages of formation, and
labeling for both EGF and the EGFR was concentrated on
the internal vesicles (Fig. 2, A–C). Quantification of EGFR
labeling showed that whereas in cells incubated with TGF
 
 
 
only 25% of the labeling was localized to inner membranes,
 
 
 
80% showed this localization upon incubation with EGF.
A similar difference in trafficking has previously been shown
between kinase active and kinase inactive EGFR (Felder et
al., 1990), demonstrating that the EGFR kinase activity is
needed for sorting of the EGFR to internal vesicles within
MVBs. In addition to labeling on MVBs, some EGFR was
found within small vesicles close to the MVBs. The nature
of these vesicles is unknown. However, as this labeling ap-
peared to be most frequent in cells incubated with TGF
 
 
 
,
the vesicles might be involved in recycling of the EGFR. Re-
cycling is probably also the reason why intracellular labeling
intensity was low upon 30 min chase upon incubation of
cells with TGF
 
 
 
. The different labeling found in our experi-
ments probably reflects the different physiological character
of EGF and TGF
 
 
 
 as EGFR ligands. EGF remains bound
to the EGFR, keeping the kinase active within MVBs,
whereas TGF
 
 
 
 is dissociated in MVBs, and the EGFR ki-
nase is no longer active (Fig. 1 B).
 
Both EGF and TGF
 
 
 
 induce polyubiquitination 
of EGFR, but the ubiquitination is more sustained 
with EGF than with TGF
 
 
 
Ubiquitination of the EGFR was studied by immunoprecip-
itating conjugated ubiquitin and immunoblotting the im-
munoprecipitated material using an antibody to EGFR. As
demonstrated in Fig. 3 A, both EGF and TGF
 
 
 
 induced
ubiquitination of the EGFR. However, the amount and af-
Figure 2.  The EGFR shows different localization within MVBs upon incubation with EGF compared with TGF . Hep2 cells incubated with 
EGF (10 nM) (A–C) or TGF  (10 nM) (D-E) on ice for 15 min and chased at 37 C for 30 min were processed for immuno-EM, sectioned and 
labeled using antibody to EGF (A) or EGFR (B–E). Upon activation with EGF, labeling for EGF (A), as well as for EGFR (B–C), is found on MVBs 
at all stages of formation. The labeling on MVBs is found on the limiting membrane (small arrowheads), as well as on internal vesicles. In 
MVBs with a high number of internal vesicles (B and C), labeling is concentrated on the inner membranes. Some labeling for the EGFR is also 
found on small vesicles within the cytoplasm (large arrowheads). In cells activated with TGF  (D–E), labeling intensity is generally reduced 
(D), and labeling is mainly localized to the outer limiting membrane of MVBs. Note that the labeling of small vesicles within the cytoplasm 
appears to be most frequent in TGF -treated cells. Bar, 100 nm. 
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finity of the antibody used could potentially be a limiting
factor with respect to immunoprecipitation of the protein of
interest. To exclude the possibility that EGF induces a
stronger initial ubiquitination than does TGF
 
 
 
, cell lysates
were subjected to SDS-PAGE and immunoblotted with an-
tibody to EGFR. By overexposing the film, we clearly ob-
served polyubiquitination of the EGFR as “upsmearing.” As
demonstrated in Fig. 3 A, top and middle, both EGF and
TGF
 
 
 
 induced the same initial ubiquitination of EGFR.
However, the ubiquitination induced by EGF was more sus-
tained than the ubiquitination induced by TGF
 
 
 
. EGF also
induced a more sustained phosphorylation of EGFR than
did TGF
 
 
 
 (Fig. 3 A, bottom). Interestingly, ubiquitination
of the EGFR occurred even at 0
 
 
 
C, before endocytosis of
EGFR (Fig. 3
 
 
 
A, top).
c-Cbl is the ubiquitin ligase responsible for the EGF-
mediated ubiquitination of the EGFR (Waterman et al., 1999;
Yokouchi et al., 1999). Therefore, we investigated activation
of c-Cbl in Hep2 cells upon EGF- and TGF
 
 
 
-induced acti-
vation of EGFR. Immunoblotting of c-Cbl immunoprecipi-
tates with antibody to phosphotyrosine showed that c-Cbl
was tyrosine phosphorylated upon incubation both with
EGF and with TGF
 
 
 
 on ice for 15 min and remained phos-
phorylated during chase at 37
 
 
 
C for 30–60 min (Fig. 3 B).
To confirm that the EGF/TGF
 
 
 
-induced ubiquitination of
the EGFR is dependent upon EGFR kinase activity, Hep2
cells were preincubated with the EGFR kinase inhibitor
PD153035 for 2 h at 37
 
 
 
C, before incubation with EGF.
PD153035 efficiently inhibited ubiquitination of the EGFR
(Fig. 3 C, left) and the tyrosine phosphorylation of c-Cbl
(Fig. 3
 
 
 
C, right).
 
TGF
 
 
 
 and EGF recruit c-Cbl to the plasma membrane, 
whereas only EGF recruits c-Cbl to endosomes
 
Immunocytochemical labeling for confocal microscopy was
performed, using antibodies to EGFR and c-Cbl. The speci-
ficity of the antibodies was investigated by Western blotting
(unpublished data) and further confirmed by ligand-induced
changes in localization of EGFR and c-Cbl. The EGFR was
mainly localized to the plasma membrane in control cells
(Fig. 4 A) and in cells incubated with EGF or TGF
 
 
 
 on ice
(Fig. 4,
 
 
 
D and G). Whereas c-Cbl in control cells mainly lo-
calized to the cytoplasm (Fig. 4 B), c-Cbl was recruited to
the plasma membrane upon incubation both with EGF and
with TGF
 
 
 
 on ice (Fig. 4,
 
 
 
E and H) and appeared to colo-
calize with the EGFR (Fig. 4,
 
 
 
F and I). In cells incubated
with EGF, both the EGFR and c-Cbl were redistributed and
colocalized on vesicular structures upon chase at 37
 
 
 
C for 15
min (Fig. 4,
 
 
 
J–L). Upon binding of TGF
 
 
 
 and further chase
at 37
 
 
 
C for 15 min, the EGFR localized both to the plasma
membrane and to vesicular structures (Fig. 4 M). However,
c-Cbl, relocalized to the cytoplasm (Fig. 4 N), and there was
no clear colocalization of EGFR and c-Cbl (Fig. 4 O).
 
Dominant negative Cbl (N-Cbl) inhibits degradation, 
but not endocytosis of EGF and EGFR
 
Ubiquitination of the EGFR at the plasma membrane could
be important for endocytosis of the EGFR. To address this,
we transiently transfected COS-1 cells with a plasmid en-
Figure 3.  Ubiquitination and phosphorylation of the EGFR 
and tyrosine phosphorylation of c-Cbl induced by EGF and 
TGF . (A) Hep2 cells were incubated with EGF (10 nM) or 
TGF  (10 nM) on ice for 15 min and chased at 37 C for indicated 
times. The cells were lysed, and the lysates were subjected to 
immunoprecipitation with antibody to conjugated ubiquitin, 
followed by immunoblotting with antibody to EGFR (top). 
Lysates were also subjected to SDS-PAGE and immunoblotting 
with antibody to EGFR (middle) or activated EGFR (pY1173) 
(bottom). c, control cells not incubated with ligand. (B) Hep2 
cells were incubated as in (A), and c-Cbl was immunoprecipitated. 
The precipitated material was subjected to SDS-PAGE and 
immunoblotting with antibody to phosphotyrosine (pTyr). c, 
control cells not incubated with ligand. (C) Hep2 cells were 
preincubated with PD153035 (100 nM) for 2 h at 37 C, before 
incubation with EGF (10 nM) on ice for 15 min. The cells were 
subsequently chased in MEM without bicarbonate containing 
PD153035 (100 nM) at 37 C for the indicated time periods. 
Conjugated ubiquitin was immunoprecipitated, and the precipitated 
material was subjected to SDS-PAGE and immunoblotting with 
antibody to EGFR (left). c-Cbl was immunoprecipitated, and the 
precipitated material was subjected to SDS-PAGE and immuno-
blotting with antibody to phosphotyrosine (pTyr) (right). 
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coding HA-tagged N-Cbl. N-Cbl consists of the NH
 
2
 
-ter-
minal 357 amino acids of c-Cbl, comprising the SH2 do-
main, but not the RING finger domain responsible for
EGFR ubiquitination. When overexpressed, N-Cbl will
bind to phosphorylated Tyr 1045 of the EGFR and inhibit
binding of c-Cbl, thereby inhibiting EGFR ubiquitination.
Transfected and nontransfected cells were compared with
respect to internalization of Rh-EGF. As demonstrated in
Fig. 5 A, cells overexpressing N-Cbl (identified with anti-
body to hemagglutinin [HA]) internalized Rh-EGF as effi-
ciently as did nontransfected cells. The rate of internaliza-
tion and degradation of EGF was further studied in COS-1
cells transfected with the plasmid encoding HA-tagged
N-Cbl. As demonstrated in Fig. 5 B, the internalization of
 
125
 
I-EGF (0.2 nM) was not altered upon transfection with
the N-Cbl plasmid. Degradation and recycling was investi-
gated upon loading transfected cells with 
 
125
 
I-EGF (8.5 nM).
Degradation was clearly inhibited, and recycling was in-
Figure. 4.  Localization of EGFR and 
c-Cbl upon incubation with EGF and 
TGF . Hep2 cells were incubated with-
out ligand (A–C) or with EGF (10 nM) 
(D–F and J–L) or TGF  (10 nM) (G–I and 
M–O) on ice for 15 min. In J–O, the cells 
were further chased at 37 C for 15 min. 
The cells were processed and immuno-
stained, as described in Materials and 
methods, using sheep anti-EGFR (1:500) 
and rabbit anti–c-Cbl (1:500), followed 
by Cy™2-conjugated donkey anti-sheep 
(1:250) (green) and Alexa Fluor 594–
conjugated goat anti–rabbit (1:1,000) 
(red). In nonstimulated cells the EGFR is 
concentrated at the plasma membrane 
(A, arrowhead), whereas c-Cbl is localized 
to the cytoplasm. Upon incubation with 
EGF or TGF  on ice, c-Cbl is recruited to 
the plasma membrane and colocalizes 
with EGFR (D–I, arrowheads). The EGFR 
colocalizes with c-Cbl in vesicular com-
partments upon incubation with EGF 
and chase at 37 C for 15 min, as indicated 
by arrowheads in J–L. After incubation 
with TGF  and chase at 37 C for 15 
min the EGFR is localized at the plasma 
membrane, and c-Cbl is localized to the 
cytoplasm, giving no colocalization. 
Bar, 50  m. 
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creased (Fig. 5 C). The degradation (Fig. 5 D) as well as the
ubiquitination (Fig. 5 E) of the EGFR was inhibited in
N-Cbl–transfected cells. The data presented are an underes-
timate of the actual effects of overexpression of N-Cbl, as the
transfection efficiency was  20% (estimated as the percent-
age of cells reactive to anti-HA antibody). The data reflected
degradation/recycling/ubiquitination in the total cell popu-
lation. Together, the data support the notion that ubiquiti-
nation of the EGFR does not promote internalization, but is
instrumental in sorting the EGFR from early to late endo-
somes.
NH4Cl, MG132 and lactacystin inhibit EGF-mediated 
degradation of the EGFR
The differential effect of EGF and TGF  with respect to
degradation of the EGFR cannot be explained by differences
in initial ubiquitination, nor by differences in endocytosis.
However, only EGF caused a sustained ubiquitination,
probably induced upon endocytosis. Degradation of the
liganded EGFR is known to occur in lysosomes (Carpenter
and Cohen, 1976; King et al., 1980a, 1980b). However, in
analogy with other ubiquitinated receptors, proteasomes
could additionally be involved in the degradation of the
EGFR. To study this possibility, we investigated the effect of
NH4Cl, which counteracts the acidification of endocytic
vesicles, and of the proteasomal inhibitors MG132 and lac-
tacystin, on EGFR degradation. Hep2 cells were incubated
with EGF (10 nM) in the presence of CHX and in the pres-
ence or absence of NH4Cl, MG132 or lactacystin. As dem-
onstrated in Fig. 6 A, NH4Cl, MG132, and lactacystin all
inhibited degradation of the EGFR, and MG132 was the
most potent inhibitor of degradation. The observed EGFR
degradation was the same when an antibody raised against
the extracellular part of the EGFR was used (unpublished
data). The data strongly suggest that lysosomal degradation
of EGFR depends on proteasomal activity. We also investi-
gated the effect of the same inhibitors with respect to EGFR
activation by immunoblotting with an antibody to pY1173.
As demonstrated in Fig. 6 B, phosphorylation of EGFR was
sustained in the presence of NH4Cl, MG132 and lactacys-
tin, and MG132 affected the phosphorylation most effi-
ciently. The sustained phosphorylation most likely reflects
inhibited degradation of the phosphorylated receptor.
To exclude the possibility that the inhibition of EGFR
degradation was a result of inhibited endocytosis, internal-
ization of 0.2 nM 
125I-EGF was investigated in the presence
or absence of NH4Cl, MG132, or lactacystin. Hep2 cells
Figure 5.  Overexpression of N-Cbl does not affect the endocytosis 
of EGF, but inhibits degradation of EGF and EGFR. (A) Rh-EGF 
(10 nM) was added to COS-1 cells transfected with a plasmid 
encoding HA-tagged N-Cbl. The cells were incubated for 15 min 
at 37 C, before being fixed and immunostained with anti-HA anti-
body. The HA-N-Cbl–positive cells demonstrate green fluorescence. 
Both transfected and nontransfected cells clearly endocytosed 
Rh-EGF (red fluorescence). Bar, 25  m. (B) Mock-transfected COS-1 
cells (transfected with empty pCDNA3) or COS-1 cells transfected 
with a plasmid encoding HA-N-Cbl were incubated with 
125I-EGF 
(0.2 nM) on ice for 15 min and chased at 37 C for the indicated time 
periods. Analysis of internalized EGF ( ,  ) was performed as 
described (Skarpen et al., 1998). The data represent the mean of 
three independent experiments   SEM. (C) Mock-transfected COS-1 
cells ( ,  ) or COS-1 cells transfected with a plasmid encoding 
HA-N-Cbl ( ,  ) were loaded with 8.5 nM 
125I-EGF for 20 min at 
37 C. The cells were washed and stripped of surface-associated 
125I-EGF before being chased for indicated times. Analysis of recycled 
EGF ( ,  ), intact intracellular EGF and degraded EGF ( ,  ) was 
performed as described in Materials and methods. The fraction 
representing intact intracellular EGF was not affected by N-Cbl and 
is not demonstrated. The data represent the mean of three independent 
experiments   SEM. (D) The effect of overexpression of N-Cbl on 
degradation of EGFR was investigated by Western blotting. Mock-
transfected COS-1 cells (control) and COS-1 cells transfected with 
a plasmid encoding HA-N-Cbl were incubated without or with EGF 
(10 nM) in the presence of CHX for 3 or 5 h. The cell lysates were 
subjected to SDS-PAGE and immunoblotting with anti-EGFR anti-
body. (E) The effect of overexpression of N-Cbl on ubiquitination of 
EGFR was investigated by immunoprecipitation and Western blotting. 
EGF (10 nM) was added to mock-transfected COS-1 cells (control) 
and to N-Cbl–transfected COS-1 cells, and EGF was bound for 15 
min on ice. Then the cells were washed, and subsequently incubated 
at 37 C for 10 min. The cells were lysed and the lysate immunopre-
cipitated with antibody to conjugated ubiquitin. Immunoprecipi-
tated material was subsequently analyzed by SDS-PAGE and 
immunoblotting with anti-EGFR antibody.Ubiquitin and proteasomes in sorting of EGFR | Longva et al. 849
were preincubated with NH4Cl, MG132 or lactacystin at
37 C before incubation with 
125I-EGF on ice for 15 min.
The cells were subsequently washed and incubated at 37 C
with medium containing the inhibitors. As shown in Fig. 6
C, neither NH4Cl, MG132, nor lactacystin, had any effect
on the internalization of 
125I-EGF. Both NH4Cl and
MG132, but not lactacystin, inhibited degradation of 
125I-
EGF at the low concentration of ligand used in this experi-
Figure 6.  Degradation of the EGFR and 
125I-EGF in the presence of NH4Cl, MG132, and lactacystin. (A–C) Hep2 cells were preincubated 
with either NH4Cl, MG132 or lactacystin, as described in Materials and methods. (A) EGF (10 nM) and CHX (25  g/ml) was added, and the 
cells were further incubated at 37 C for the indicated time periods. The cells were lysed and subjected to SDS-PAGE and immunoblotting 
with antibody to EGFR. c, control cells not incubated with ligand or CHX. Both NH4Cl, MG132 and lactacystin inhibited the degradation of 
EGFR. The presented data is representative of seven independent experiments. (B) EGF (10 nM) was added to cells on ice for 15 min before 
chase at 37 C for the indicated times in medium containing the same inhibitors as during the preincubation. The cells were lysed and subjected 
to SDS-PAGE and immunoblotting with antibody to activated EGFR (pY1173). c, control cells not incubated with ligand. (C) Cells preincubated 
with or without inhibitors were incubated with 
125I-EGF (0.2 nM) on ice for 15 min and chased in medium containing the inhibitors at 37 C 
for the indicated time periods. Analysis of EGF in the medium ( ), EGF at the cell surface ( ), internalized EGF ( ) and degraded EGF ( ) 
was performed as described (Skarpen et al., 1998). Both NH4Cl and MG132, but not lactacystin, inhibited the degradation of 
125I-EGF. (D) 
Hep2 cells were preincubated for 2 h with and without lactacystin. The cells were then loaded with 8.5 nM 
125I-EGF for 20 min at 37 C, and 
recycling and degradation was investigated as described in Fig. 5 C. Lactacystin was found to enhance recycling and to inhibit degradation of 
125I-EGF. The fraction representing intact intracellular EGF was not affected by lactacystin and is not demonstrated. The data in C and D 
represent the mean of 3 independent experiments   SEM.850 The Journal of Cell Biology | Volume 156, Number 5, 2002
ment. To study effects of lactacystin on recycling and degra-
dation of EGFR-bound EGF, 8.5 nM 
125I-EGF was used,
and the analysis was performed essentially as described
(Babst et al., 2000). As demonstrated in Fig. 6 D, lactacystin
slightly enhanced recycling and inhibited degradation of
125I-EGF. The fact that lactacystin inhibits degradation of
EGFR-bound EGF at high ligand concentration suggests
that proteasomal activity is involved in efficient delivery to
an environment where EGF is degraded.
The finding that MG132, but not lactacystin, inhibits
degradation of very low concentrations of EGF can be ex-
plained by the possibility that MG132, which is a peptide al-
dehyde, does not specifically inhibit proteasomal proteases.
We used a Cathepsin B enzyme assay to study the potential
effect of MG132 and lactacystin on Cathepsin B, reported
to be important for degradation of EGF and EGFR (Authier
et al., 1999). We found that MG132 caused an 80% in-
hibition of Cathepsin B, whereas lactacystin only slightly
( 10%) inhibited Cathepsin B. Therefore, the strong inhib-
itory effect of MG132 on degradation of EGF can be ex-
plained by the inhibitory effect of MG132 on Cathepsin B.
The effect of lactacystin on ligand-induced trafficking of
the EGFR was further studied by immuno-EM. Control
cells or cells pretreated with lactacystin or MG132 were in-
cubated with EGF (10 nM) for 15 min on ice, followed by
chase in ligand-free, prewarmed medium with inhibitor. Af-
ter 1 h chase, both EGF and the EGFR (unpublished data)
localized to MVBs. However, both the appearance of MVBs
and the distribution of EGF and EGFR inside MVBs were
different in control cells compared with in cells treated with
lactacystin and MG132. In control cells the labeling for
EGF was found in MVBs with a high number of internal
vesicles, and  80% of the labeling localized to these internal
membranes (Fig. 7 A). In cells treated with lactacystin or
MG132 (Fig. 7 B; unpublished data), labeling for EGF was
mainly found on MVBs with few internal vesicles, and
 60% of the labeling was on the outer limiting membrane.
This shows that proteasomal activity is involved in the trans-
location of EGFR from the limiting membrane to internal
membranes within MVBs.
To investigate whether proteasomal inhibitors affected all
intracellular sorting, we studied the fluid phase endocytosis
of BSA-coated colloidal gold. As demonstrated in Fig. 7 C,
BSA-gold was transported efficiently to MVBs filled with in-
ternal membranes, demonstrating that lactacystin did not af-
fect formation of MVBs in general.
To characterize the endosomes to which EGF and EGFR
localize in the presence of lactacystin more closely, we added
Rh-EGF and FITC-transferrin (Tf) to cells in the presence
or absence of lactacystin. Upon incubation for 15 min, most
EGF colocalized with Tf. Upon incubation for 60 min,
there was no significantly increased colocalization of EGF
and Tf in lactacystin-treated cells, compared with control
cells (unpublished data). Therefore, the endosomes depicted
in Fig. 7 B do not appear to be part of the recycling com-
partment.
Proteasomal inhibitors do not inhibit degradation of 
EGF-EGFR by depleting cellular ubiquitin
A side effect of incubating cells with proteasomal inhibitors
could be depletion of intracellular ubiquitin (Swaminathan
et al., 1999). Therefore, we investigated the effect on EGFR
ubiquitination of incubating Hep2 cells with lactacystin for
3 and 5 h. Hep2 cells were preincubated with both lactacys-
tin and CHX for 3 and 5 h (the same way degradation of
EGFR was studied). As shown in Fig. 8, the EGFR was
ubiquitinated equally efficiently by addition of EGF regard-
less of preincubation with lactacystin. This demonstrates
Figure 7.  Translocation of EGF-EGFR to internal membranes of 
MVBs depends on proteasomal activity. Control and lactacystin-
treated Hep2 cells were incubated with EGF for 15 min on ice 
followed by chase in EGF free medium at 37 C for 1 h. To localize 
endocytosed EGF, ultra-thin frozen sections were labeled with anti-
EGF antibodies followed by 15 nm protein A gold. In control cells 
(A) EGF is localized within MVBs with a high number of internal 
vesicles, and small amounts of labeling is also found within electron 
dense, compact MVBs (arrowhead). In lactacystin-treated cells (B) 
EGF is localized to MVBs with very few internal vesicles. (C) 
Lactacystin-treated Hep2 cells (preincubated for 2 h) were incubated 
with 10 nm BSA-gold for 60 min at 37 C. Endocytosed gold was 
found to localize within MVBs with high numbers of internal 
vesicles. Bars, 100 nm.
Figure 8.  Preincubation of Hep2 cells with lactacystin for 3 and 
5 h does not inhibit subsequent EGF-induced ubiquitination of the 
EGFR. Hep2 cells were preincubated with or without lactacystin 
and CHX for 3 or 5 h. Then control cells and cells pretreated with 
lactacystin/CHX were incubated without or with EGF for 15 min on 
ice before being washed and incubated at 37 C for 10 min. The cell 
lysates were subjected to SDS-PAGE and immunoblotting with anti-
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that reduction of intracellular ubiquitin resulting from pre-
incubation of cells with lactacystin was not sufficient to in-
hibit EGF-induced polyubiquitination of the EGFR and
strongly supports the notion that proteasomal activity is es-
sential for efficient transport of EGF-bound EGFR to inner
membranes of MVBs.
The EGFR is not a direct target of proteasomal proteases
An important consideration is the nature of the proteasomal
substrate. To clarify whether the EGFR is itself cleaved dur-
ing sorting to MVBs, we transfected Hep2 cells with a plas-
mid encoding the EGFR–green fluorescent protein (GFP)
fusion protein. This fusion protein is endocytosed and de-
graded exactly like wild-type EGFR upon binding EGF
(Carter and Sorkin, 1998). Therefore, we investigated by
immuno-EM whether or not GFP could be detected on in-
ner membranes of MVBs. As illustrated in Fig. 9, we found
that upon incubation of the cells with EGF for 30 min at
37 C, labeling for the EGFR as well as for GFP could be de-
tected both on the limiting and internal membranes of
MVBs. Quantification showed that  60% of anti-EGFR la-
beling and 50% of the anti-GFP labeling localized to the in-
ternal membranes. As the anti-EGFR antibody recognizes
the cytosolic part of the EGFR and GFP is a COOH-termi-
nal extension of the EGFR, the experiment demonstrates
that the cytosolic part of the EGFR is intact even when the
EGFR localizes to internal membranes of MVBs. This
shows that although proteasomal activity is needed for effi-
cient translocation of EGFR to internal membranes of
MVBs, the EGFR itself is not a direct proteasomal target.
Discussion
In the present work we have expanded on our previous ob-
servation that the EGFR was polyubiquitinated at the
plasma membrane (Stang et al., 2000). We have studied
EGFR ubiquitination using Hep2 cells, and we now report
that the EGFR becomes polyubiquitinated even when cells
are incubated with ligand on ice. As endocytosis of the
EGFR does not happen when cells are incubated on ice, our
results confirm the finding that EGFR is ubiquitinated at
the plasma membrane before endocytosis. Consistently, we
observed tyrosine phosphorylation of c-Cbl and recruitment
of c-Cbl to the plasma membrane upon activation of the
EGFR on ice. A possible scenario is that c-Cbl–dependent
ubiquitination is important for ligand-induced endocytosis
of the EGFR. This would be in agreement with the conclu-
sion that c-Cbl is required for endocytosis of the colony
stimulating factor-1 receptor (Wang et al., 1996, 1999; Lee
et al., 1999). However, our present results demonstrate that
overexpression of N-Cbl, which acts dominant negatively
with respect to ubiquitination of the EGFR, does not affect
EGFR endocytosis. This is in accordance with previously
published views (Levkowitz et al., 1998; Thien et al., 2001).
We have taken advantage of the two different EGFR
ligands, EGF and TGF , to induce different trafficking of
the EGFR upon endocytosis. Interestingly, both ligands ini-
tially induced ubiquitination and endocytosis of the EGFR
to the same extent, even though TGF  very inefficiently in-
duced transport of the EGFR to internal vesicles of MVBs
and lysosomal degradation of the EGFR. This clearly illus-
trates that the initial ubiquitination induced by activation of
the EGFR is not a signal for lysosomal sorting. It should be
noted that the ubiquitination induced by EGF lasted longer
than the ubiquitination induced by TGF . The sustained
ubiquitination induced by EGF correlated with the sus-
tained tyrosine phosphorylation of the EGFR and c-Cbl,
and therefore the sustained kinase activity of the EGFR. Be-
cause EGFR kinase activity has been demonstrated to be re-
quired for transport of the EGFR from the limiting mem-
brane to the internal vesicles of MVBs (Felder et al., 1990),
the sustained ubiquitination seen upon incubation with
EGF could be important for trafficking of EGFR to lyso-
somes. Interestingly, Katzmann et al. (2001) recently re-
ported ubiquitin-dependent sorting of the vacuolar hydro-
lase carboxypeptidase S to internal membranes of MVBs in
yeast. They further characterized a conserved endosomal
sorting complex containing the protein Vps23. This protein
contains a ubiquitin conjugating–like domain (Babst et al.,
2000). The mammalian homologue of Vps23 is the protein
encoded by the tumor susceptibility gene 101 (Tsg101), and
this protein has been demonstrated to function in late endo-
somal trafficking. In fact, in tsg 101 mutant cells, endocy-
tosed EGFR was rapidly recycled back to the cell surface and
inefficiently degraded (Babst et al., 2000). Katzmann et al.
proposes a model whereby ubiquitinated proteins bind to
the sorting complex containing Vps23. Several other class E
Vps proteins are suggested to be important for the subse-
quent sorting, as well as for recruitment of deubiquitinating
enzymes, like Doa4 (Katzmann et al., 2001).
The importance of proteasomal activity in lysosomal traf-
ficking of EGFR is supported by our finding that lactacystin
inhibits degradation of the EGFR as efficiently as does
NH4Cl. Our present immuno-EM data show that inhibition
of proteasomal activity with lactacystin causes retention of
EGFR in MVBs at an early stage of formation. Consistently,
Figure 9.  The COOH-terminal part of EGFR–GFP is intact upon 
translocation of EGFR to inner membranes of MVBs. Hep2 cells 
transfected with EGFR-GFP, as described in Materials and methods, 
were incubated with 10 nM EGF for 30 min at 37 C before processing 
for immuno-EM. Thawed cryosections were double labeled using 
anti-GFP antibodies followed by 15 nm protein A gold and anti-
EGFR antibodies followed by 10 nm protein A gold (arrowheads). 
The results show that both GFP- and EGFR-labeling localize to 
the limiting membrane as well as to inner membranes of MVBs. 
Bar, 100 nm.852 The Journal of Cell Biology | Volume 156, Number 5, 2002
we found, as did Levkowitz et al. (1998), that inhibition of
proteasomes promoted recycling and inhibited degradation
of EGF. However, the effect of lactacystin on recycling and
degradation of EGF was smaller than the effect observed in
tsg 101 mutant cells (Babst et al., 2000) and smaller than the
effect observed upon overexpression of N-Cbl (transfection
efficiency considered). That degradation of EGF is inhibited
more efficiently by overexpression of N-Cbl and in tsg 101
mutant cells compared with in cells incubated with lactacys-
tin, suggests the involvement of proteasomes downstream of
ubiquitinated EGFR interacting with a complex containing
Tsg 101. Our data show that proteasomal activity is not re-
quired for the formation of MVBs in general, as lactacystin
does not inhibit transport of BSA-gold to MVBs. Morpho-
logically the EGF/EGFR positive compartments found upon
inhibition of proteasomal activity resembled the EGFR posi-
tive compartments found upon incubation with TGF . We
found no significantly increased colocalization of EGF and
Tf upon incubating cells with lactacystin.
Although ubiquitinated EGFR can be recognized and de-
graded by purified 26S proteasomes in vitro (Levkowitz et al.,
1999), our results show that the cytosolic part of the EGFR is
intact on internal membranes of MVBs, and therefore dem-
onstrate that the EGFR itself is not a direct proteasomal target
in vivo. It was earlier also demonstrated that although the
ubiquitination machinery and proteasomal activity is needed
for degradation of the growth hormone receptor, neither the
cytosolic tail of the growth hormone receptor is a proteasomal
target (van Kerkhof et al., 2001). Therefore, the nature of the
proteasomal target(s) is still unclear.
In conclusion, our data demonstrate that there is an initial
ubiquitination of the EGFR at the plasma membrane, but that
this ubiquitination per se does not encode EGFR degradation
and that initiation of endocytosis of the EGFR does not de-
pend on ubiquitination. Upon conditions where the EGFR
kinase activity is secured, the ubiquitination of the EGFR is
sustained. Eventually, activated EGFR is efficiently trans-
ported to internal vesicles of MVBs in a proteasome depen-
dent process. Therefore, the sustained ubiquitination of the
EGFR seems to be a way of engaging ubiquitin-interacting
proteins, and proteasomal cleavage eventually facilitates the
transport of the EGFR to a highly degrading environment.
Materials and methods
Materials
Human recombinant EGF was from Bachem Feinchemikalien AG, human
recombinant TGF  was from R&D Systems, Inc., 
125I-EGF was from Amer-
sham Pharmacia Biotech, MG132 from Affiniti Research Products Ltd., and
PD153035 was from Tocris Cookson Ltd. EZ-link sulfo-NHS-LC-Biotin was
from Perbio Science Ltd., alkaline phosphatase–conjugated streptavidine
from Dako Corporation, and rhodamin-EGF (Rh-EGF) and FITC-Tf were from
Molecular Probes, Inc. BSA-gold was prepared according to Slot and Geuze
(Slot and Geuze, 1985). Fugene was from Roche Diagnostics Corporation.
Other chemicals were from Sigma-Aldrich unless otherwise noted.
Cell culture and treatment
Hep2 and COS-1 cells were grown in DME (BioWhittaker) containing pen-
icillin–streptomycin–fungizone mixture (BioWhittaker), L-glutamine (2
mM) (BioWhittaker), and FBS (BioWhittaker) (5% vol/vol in the case of
Hep2 cells and 10% for COS-1 cells). The cells were plated at a density of
15,000 cells/cm
2 48 h before experiments. In pulse-chase experiments,
cells were incubated with ligand in MEM without bicarbonate with 0.1%
BSA on ice for 15 min, followed by washing three times in ice-cold PBS to
remove unbound ligand, and subsequent chase in ligand-free MEM with-
out bicarbonate at 37 C.
Antibodies
Sheep anti-EGFR was from Gibco Life Technologies, and Fitzgerald Indus-
tries International, Inc., rabbit anti-EGFR, rabbit anti-EGF, and rabbit anti–
c-Cbl from Santa Cruz Biotechnology, Inc., mouse antiactivated EGFR
(pY1173) and mouse anti-phosphotyrosine from Upstate Biotechnology,
rabbit anticonjugated ubiquitin from Sigma-Aldrich, mouse anti-hemag-
glutinin (HA) from Roche Diagnostics, rabbit anti-GFP from AbCam Ltd.,
rabbit anti-mouse IgG from Cappel, ICN Biomedicals. Peroxidase-conju-
gated donkey anti–sheep, peroxidase-conjugated donkey anti–mouse,
Cy
TM2-conjugated donkey anti–sheep and rabbit anti–sheep IgG were all
from Jackson ImmunoResearch Laboratories. Alexa Fluor 594–conjugated
goat anti–rabbit was from Molecular Probes.
Immunoprecipitation
Cells were lysed in immunoprecipitation buffer, as described (Stang et al.,
2000). Protein A or protein G–coupled Sepharose beads (Amersham Phar-
macia Biotech) were incubated with antibody for 1 h at room temperature
and subsequently washed twice with immunoprecipitation buffer, before
the cell lysates were added. Immunoprecipitation was performed at 4 C for
1 h. Immunoprecipitation with antibody to conjugated ubiquitin and SDS-
PAGE and immunoblotting was performed as described (Stang et al.,
2000).
Biotinylation of surface-localized EGFR
Biotinylation was performed at 4 C, essentially as described (Corbeil et al.,
1999), using 2 mM biotin. The EGFR was immunoprecipitated using rabbit
anti-EGFR and protein A–coupled Sepharose beads (Amersham Pharmacia
Biotech). The immunoprecipitate was subjected to SDS-PAGE and elec-
trotransferred to PVDF transfer membrane (Hybond-P; Amersham Pharma-
cia Biotech). The membrane was incubated with alkaline phosphatase–
conjugated streptavidin or with sheep anti-EGFR antibody and alkaline
phosphatase-conjugated anti–sheep antibody. Reactive bands were ana-
lyzed by enhanced chemifluoresence (Amersham Pharmacia Biotech). The
band intensity was measured using a phosphorofluoroImager (Molecular
Imager FX; Bio-Rad Laboratories).
Plasmids and transfection of cells
The plasmid EGFR-GFP, encoding a fusion protein of EGFR and enhanced
GFP (Carter and Sorkin, 1998) was provided by Dr. Alexander Sorkin.
Hep2 cells were transfected with this plasmid using Fugene 24 h upon
plating. HA-tagged c-Cbl in the pJZenNeo vector (Andoniou et al., 1994)
was provided by Dr. Robin M. Scaife. By polymerase chain reaction a
1,121-bp fragment, corresponding to the HA tag and the 357 amino acids
constituting N-Cbl was subcloned into pCDNA3. This plasmid was trans-
fected into COS-1 cells using Fugene 24 h after plating. Transfected cells
were analyzed 48 h after transfection.
Immunocytochemistry and confocal microscopy
Cells were plated on 12-mm coverslips (MENZEL-GLÄSER
®). After experi-
ments, cells were washed once in cytoskeleton buffer (NaCl [137 mM],
KCl [5 mM], Na2HP04 [1.1 mM], KH2PO4 [0.4 mM], glucose [5.5 mM],
NaHCO3 [4 mM], MES [10 mM], EGTA [2 mM], MgCl2 [2 mM]) and sub-
sequently fixed with paraformaldehyde (4% wt/vol) (Riedel-de Haën AG)
in Soerensen’s phosphate buffer for 20 min on ice. Cells were washed
three times with cytoskeleton buffer before permeabilization with Triton
X-100 (0.1% wt/vol in cytoskeleton buffer) for 10 min. The fixed and per-
meabilized cells were preincubated with BSA (1% wt/vol in PBS) for 30
min before incubation with primary antibodies for 1 h. The coverslips were
washed with PBS and incubated with secondary antibodies for 30 min be-
fore mounting with Dako fluorescent mounting medium with NaN3 (15
mM). The cells were examined using a confocal microscope (Leica TCS).
125I-EGF interaction experiments
The cells were incubated as described in legends to Figs. 5 and 6. Internal-
ization and degradation of EGF was analyzed as previously described
(Skarpen et al., 1998). Additionally, recycling of EGF was analyzed essen-
tially as described (Babst et al., 2000), loading cells with 8.5 nM 
125I-EGF
in MEM without bicarbonate and with 0.1% BSA. Upon loading, the sur-
face-localized radioactivity was removed by a glycine-buffered solution,
pH 3.0 (Babst et al., 2000). Upon chase at 37 C, the medium was analyzed
for degraded and recycled EGF as described (Skarpen et al., 1998), and the
cells were analyzed for recycled EGF (released by the pH 3.0 buffer) and
for internalized EGF (cells solubilized by 1 M NaOH after treatment withUbiquitin and proteasomes in sorting of EGFR | Longva et al. 853
low pH). The cpm representing recycled EGF in the medium and at the cell
surface were combined in one fraction.
Inhibition of lysosomal or proteasomal activity
Hep2 cells were preincubated with either NH4Cl (10 mM) for 10 min,
MG132 (10  M) or lactacystin (50  M) for 1 or 2 h at 37 C. To measure
degradation of the EGFR, EGF (10 nM) and CHX (25  g/ml) were added
and the cells incubated at 37 C for the indicated times. Cells were lysed
and subjected to SDS-PAGE and immunoblotting with antibody to EGFR.
For immuno-EM, cells preincubated with the different inhibitors were in-
cubated with EGF (10 nM) on ice for 15 min followed by chase at 37 C for
the indicated time periods in the presence of inhibitors.
Cathepsin B enzyme assay
The activity of Cathepsin B (Calbiochem) in the presence of lactacystin and
MG132 was analyzed by use of Colorimetric Substrate I (Calbiochem) ac-
cording to the manufacturer’s instructions. The enzyme assay was per-
formed three times with three parallels for each condition.
Immuno-EM
The cells were incubated as described in legends to figures. The cells were
subsequently washed with PBS, fixed with paraformaldehyde (4% wt/vol)
and glutaraldehyde (0.1% wt/vol) in Sorensen’s phosphate buffer and pro-
cessed for cryosectioning and immunolabeling (Griffiths et al., 1984).
Bound antibodies were visualized using protein A gold, a gift of Dr. G.
Posthuma. When the primary antibody was mouse or sheep IgG, incuba-
tion with rabbit anti–mouse or rabbit anti–sheep IgG was used as an inter-
mediate step between the primary antibody and protein A gold. The sec-
tions were examined using a Philips CM 120 electron microscope. To
quantify labeling of MVBs, the total number of gold particles found on
MVBs (100%) were divided into two groups, gold particles associated with
the outer limiting membrane and gold particles associated with internal
membranes, and the percentage distribution of the labeling was calcu-
lated. In each experiment a minimum of 100 gold particles were counted
on MVBs.
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